CymaBay Announces Proposed Public Offering of Common Stock

NEWARK, Calif., July 17, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it intends to offer and sell 10,000,000 shares of its common stock, subject to market and other conditions, in an underwritten public offering.   In connection with this offering, CymaBay Therapeutics, Inc. expects to grant the underwriters a 30-day option to purchase up to 1,500,000 additional shares of common stock. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.  CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar and for working capital and general corporate purposes.

Leerink Partners LLC, Piper Jaffray & Co. and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering.

The securities described above are being offered by CymaBay pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC").  A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from: Leerink Partners LLC, Attn: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts  02110, by telephone at (800) 808-7525, ext. 6132, or by email at [email protected]; Piper Jaffray & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, or by calling (800) 747-3924, or by email at [email protected]; or Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CymaBay

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). A Phase 2 study of seladelpar established proof of concept in PBC. CymaBay is currently conducting a second Phase 2 study of seladelpar in PBC in order to support dose selection for Phase 3.

Cautionary Statements

This announcement contains forward-looking statements, including statements relating to CymaBay’s expectations regarding the timing of the proposed public offering and anticipated use of proceeds. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. CymaBay cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the public offering. There can be no assurance that CymaBay will be able to complete the public offering on the anticipated terms, or at all. Risks and uncertainties relating to CymaBay and its business can be found in the “Risk Factors” section of CymaBay’s Form 10-K for the year ended December 31, 2016, filed with the SEC on March 23, 2017, and Form 10-Q for the quarter ended March 31, 2017, filed with the SEC on May 11, 2017, and in the preliminary prospectus related to the proposed offering filed with the SEC on or about July 17, 2017. CymaBay undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in CymaBay’s expectations.

Contacts:
Sujal Shah
CymaBay Therapeutics, Inc.
(510) 293-8800
[email protected]
or
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
[email protected]